BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C059I2
Authority: BE; Belgium

Application number

BE2016C059C

Other languages

Dutch (nl)

Original Assignee

Novozymes Biopharma Dk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2016-11-04

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-04 Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As

2020-08-20 Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)

BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US19938400P	2000-04-25	2000-04-25
US25693100P	2000-12-21	2000-12-21
EP01934875A EP1278767A4 (fr)	2000-04-12	2001-04-12	Proteines fusionnees a l'albumine
EP08075909A EP2067488A1 (fr)	2000-04-12	2001-04-12	Protéines de fusion d'albumine
EP06076852A EP1832599A3 (fr)	2000-04-12	2001-04-12	Proteines de fusion d'albumine

Publications (1)

Publication Number	Publication Date
BE2016C059I2 true BE2016C059I2 (fr)	2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C059C BE2016C059I2 (fr)	2000-04-12	2016-11-04

Country Status (10)

Country	Link
US (23)	US6994857B2 (fr)
EP (21)	EP1274720A4 (fr)
JP (9)	JP2003530852A (fr)
AU (7)	AU2001264563A1 (fr)
BE (1)	BE2016C059I2 (fr)
CA (8)	CA2405563A1 (fr)
DK (2)	DK2236152T3 (fr)
ES (2)	ES2529300T3 (fr)
FR (1)	FR16C0043I2 (fr)
WO (7)	WO2001079442A2 (fr)

Families Citing this family (679)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2002028877A1 (fr) *	2000-09-29	2002-04-11	Human Genome Sciences, Inc.	24 proteines humaines secretees
WO2001034626A1 (fr) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	28 proteines secretees humaines
WO2001034627A1 (fr) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	28 proteines humaines secretees
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (fr) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Semaphorine L humaine et murine
US20030104538A1 (en) *	1997-09-18	2003-06-05	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (de) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
KR20020002354A (ko)	1998-10-13	2002-01-09	추후제출	안정화된 생활성 펩티드 및 이들을 동정, 합성 및이용하는 방법
CA2372464C (fr) *	1999-05-05	2012-07-31	Phylogica Limited	Isolation de modulateurs biologiques a partir de banques de fragments de genes presentant une diversite biologique
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US20020049312A1 (en) *	2000-05-23	2002-04-25	Turner C. Alexander	Noel human thrombospondin-like proteins and polynucleotides encoding the same
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
EP1224285A4 (fr) *	1999-10-29	2004-12-08	Human Genome Sciences Inc	27 proteines humaines secretees
CA2388019A1 (fr) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	24 proteines humaines secretees
EP1234031B2 (fr)	1999-11-30	2021-11-24	Mayo Foundation For Medical Education And Research	Nouvelle molécule immunorégulatrice b7-h1,
US7608681B2 (en)	1999-12-24	2009-10-27	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
EP1274720A4 (fr) *	2000-04-12	2004-08-18	Human Genome Sciences Inc	Proteines fusionnees a l'albumine
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
EP1285066A1 (fr) *	2000-05-12	2003-02-26	MERCK PATENT GmbH	Proteine de boite f
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
WO2001094413A2 (fr)	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation
WO2001094391A2 (fr) *	2000-06-08	2001-12-13	Incyte Genomics, Inc.	Proteines de signalisation intracellulaires
EP1294871A1 (fr) *	2000-06-21	2003-03-26	Amgen, Inc.	Polypeptides stromaux-1 epitheliaux secretes du colon, acides nucleiques codant pour ces polypeptides, et leurs utilisations
EP1317468A4 (fr) *	2000-08-18	2004-07-07	Human Genome Sciences Inc	23 proteines humaines secretees
AU2001229509A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	11 human secreted proteins
AU2001229507A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	21 human secreted proteins
EP1313761A4 (fr) *	2000-08-28	2005-01-26	Human Genome Sciences Inc	18 proteines humaines secretees
EP1322659A4 (fr) *	2000-09-20	2005-01-26	Human Genome Sciences Inc	21 proteines humaines secretees
AU2001296235A1 (en) *	2000-10-12	2002-04-22	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002046228A2 (fr) *	2000-12-05	2002-06-13	Wisconsin Alumni Research Foundation	Recepteur de la toxine du b. anthracis
ES2311560T3 (es)	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
JP4344519B2 (ja) *	2000-12-28	2009-10-14	旭化成ファーマ株式会社	ＮＦ−κＢ活性化遺伝子
EP1368468A4 (fr) *	2001-02-23	2005-02-16	Human Genome Sciences Inc	83 proteines humaines secretes
WO2002072138A1 (fr) *	2001-03-08	2002-09-19	Hyseq, Inc.	Methodes et materiels se rapportant a des polypeptides et a des polynucleotides apparentes a la fibuline
EP2280030A3 (fr)	2001-04-10	2011-06-15	Agensys, Inc.	Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7250495B2 (en)	2001-06-20	2007-07-31	Genentech, Inc.	PRO20044 polypeptides
AU2002328853A1 (en) *	2001-07-06	2003-01-21	Geneprot, Inc.	Carcinoma-related peptides
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
WO2003030821A2 (fr) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
DE10251673A1 (de)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) *	2001-11-16	2003-11-21	신코엠 주식회사	반도체 메모리 장치
ATE421974T1 (de)	2001-12-17	2009-02-15	Serono Lab	Chemokine mutanten, die als chemokine antagonisten wirken
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
PT1463751E (pt) *	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
EP1463752A4 (fr) *	2001-12-21	2005-07-13	Human Genome Sciences Inc	Proteines de fusion d'albumine
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
CA2475382A1 (fr) *	2002-02-07	2003-08-14	Delta Biotechnology Limited	Peptides anti-angiogenese hybrides avec l'albumine
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
JP4429728B2 (ja) *	2002-02-21	2010-03-10	ワイスエルエルシー	フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
WO2003075742A2 (fr) *	2002-03-05	2003-09-18	Merck & Co., Inc.	Marqueur biologique indiquant l'efficacite des medicaments coupe-faim
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2482856A1 (fr) *	2002-04-15	2003-10-30	American National Red Cross	Ligands de liaison a des proteines plasmatiques
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
AU2003234136A1 (en)	2002-04-18	2003-11-03	The General Hospital Corporation	Drg11-responsive (dragon) gene family
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en)	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
DK2311432T3 (en)	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DK1531850T3 (da) *	2002-06-07	2012-06-04	Zymogenetics Inc	Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN101172091B (zh) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
CN1241946C (zh)	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004005520A1 (fr) *	2002-07-03	2004-01-15	Nexgen Biotechnologies, Inc.	Procede de preparation d'un polypeptide de fusion comportant le facteur de croissance epidermique et de l'albumine serique humaine dans des plantes
EP1572130A4 (fr) *	2002-07-08	2008-07-02	Genentech Inc	Compositions et procedes destines au traitement de maladies liees au systeme immunitaire
AU2003281626A1 (en) *	2002-07-22	2004-02-09	Masayoshi Harigai	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
WO2004015113A2 (fr) *	2002-08-07	2004-02-19	Delta Biotechnology Ltd.	Facteur neurotrophique ciliaire hybride avec l'albumine
WO2004014315A2 (fr) *	2002-08-13	2004-02-19	Arbios Systems, Inc.	Therapie d'echange de plasma selectif
TR201900937T4 (tr)	2002-08-28	2019-02-21	Dyax Corp	Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (es) *	2002-09-06	2017-05-30	Alexion Pharmaceuticals, Inc.	Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US20060128615A1 (en) *	2002-09-18	2006-06-15	Pierrette Gaudreau	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE60322259D1 (de) *	2002-12-20	2008-08-28	Geneos Oy	Asthma-empfindlichkeitsort
WO2004058817A1 (fr) *	2002-12-26	2004-07-15	Takeda Pharmaceutical Company Limited	Nouvelles proteines et leur utilisation
CA2513213C (fr) *	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
CN101444621B (zh) *	2003-02-11	2013-11-20	夏尔人类遗传性治疗公司	使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (fr) *	2003-03-12	2009-06-24	Vasgene Therapeutics Inc	Composes d'acide nucleique pouvant inhiber l'angiogenese et la croissance tumorale
WO2004082640A2 (fr) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Fragments ou polymeres d'albumine a temps de residence vasculaire modulable utilisables pour la mise au point de therapies d'administration et de vaccins
AU2004226162A1 (en) *	2003-04-04	2004-10-14	Universite De Lausanne	Peptabody for cancer treatment
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
WO2004094589A2 (fr) *	2003-04-18	2004-11-04	Incyte Corporation	Proteines secretees
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP4817233B2 (ja) *	2003-06-30	2011-11-16	学校法人日本大学	細胞外基質沈着タンパク質
WO2005010040A1 (fr)	2003-07-15	2005-02-03	Barros Research Institute	Antigene eimeria tenella utilise dans l'immunotherapie de la coccidiose
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
JP4746552B2 (ja)	2003-11-04	2011-08-10	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
ZA200605449B (en) *	2003-12-03	2007-11-28	Delta Biotechnology Ltd	Interleukin-11 fusion proteins
CN100379762C (zh) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
WO2005058961A2 (fr)	2003-12-12	2005-06-30	Amgen Inc.	Anticorps anti-galanine et leurs utilisations
WO2006067511A1 (fr)	2004-12-23	2006-06-29	Novozymes Delta Limited	Technique d'expression genetique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
JPWO2005061704A1 (ja) *	2003-12-24	2007-07-12	武田薬品工業株式会社	癌の予防・治療剤
JP5010923B2 (ja) *	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
SE0400489D0 (sv) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
WO2005085472A2 (fr) *	2004-03-03	2005-09-15	Evotec Neurosciences Gmbh	Utilisation diagnostique et therapeutique du gene et de la proteine mal2 pour les maladies neurodegenerescentes
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
WO2005091891A2 (fr) *	2004-03-11	2005-10-06	Kythera Biopharmaceuticals, Inc.	Compositions et methodes permettant de prevenir et de traiter des maladies de la peau et des cheveux
DE602005025459D1 (de)	2004-03-12	2011-02-03	Vasgene Therapeutics Inc	Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US9592277B2 (en) *	2004-04-14	2017-03-14	Avirid, Inc.	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
CA2564031A1 (fr) *	2004-04-23	2005-11-03	Conjuchem Biotechnologies Inc.	Procede de purification de conjugues d'albumine
KR100599454B1 (ko) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	종양 억제자로 작용하는 ａｉｍ3의 신규 용도
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8008020B2 (en) *	2004-06-03	2011-08-30	Vermillion, Inc.	Biomarkers for peripheral artery disease
CN101005828B (zh) *	2004-06-17	2012-01-11	维尔恩公司	用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
CA2573720A1 (fr)	2004-07-14	2006-02-23	University Of Utah Research Foundation	Compositions et utilisations liees a des netrines
CN102680686A (zh) *	2004-08-13	2012-09-19	千年药品公司	用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
AU2005286770A1 (en)	2004-09-21	2006-03-30	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2581423A1 (fr)	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (fr) *	2004-10-01	2006-04-13	Cell Ionix, Inc.	Procede et formule s'appliquant a la stimulation, au ciblage, a la liberation, a la circulation et a la reagregation des cellules souches
DK3428191T3 (da) *	2004-10-06	2025-01-02	Mayo Found Medical Education & Res	B7-h1 og pd-1 til behandling af renalcellekarcinom
WO2006042197A2 (fr) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Utilisation de del-1 dans une regeneration de cheveux, d'os et de cartilage
KR101310511B1 (ko)	2004-10-25	2013-09-25	임뮨 시스템 키 리미티드	흉선-특이성 단백질
KR100583350B1 (ko) *	2004-11-03	2006-06-05	(주)넥스젠	Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
DE602005009856D1 (de) *	2004-11-09	2008-10-30	Ares Trading Sa	Verfahren zur reinigung von fsh
WO2006072625A2 (fr)	2005-01-06	2006-07-13	Novo Nordisk A/S	Procedes et traitements combines anti-kir
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-CD19 antibodies and their applications in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
EP1864138A2 (fr) *	2005-03-23	2007-12-12	Wyeth	Detection d'agents modulateurs de gdf-8
CN101137906A (zh) *	2005-03-23	2008-03-05	惠氏公司	对gdf-8调节剂的免疫应答的检测
MX2007012887A (es)	2005-04-18	2007-12-10	Novo Nordisk As	Variantes il-21.
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
ES2417065T3 (es)	2005-04-26	2013-08-05	Trion Pharma Gmbh	Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US8653028B2 (en) *	2005-04-29	2014-02-18	Rui Rong Yuan	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
AU2006244445B2 (en)	2005-05-05	2013-04-18	Duke University	Anti-CD19 antibody therapy for autoimmune disease
EP1951749A2 (fr) *	2005-05-12	2008-08-06	Zymogenetics, Inc.	Procédés d'utilisation de phhla2 pour une stimulation conjointe des lymphocytes t
KR101510065B1 (ko)	2005-06-08	2015-04-07	다나-파버 캔서 인스티튜트 인크.	예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
WO2007014167A2 (fr) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
HUE029465T2 (en)	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
DK1917276T3 (en)	2005-08-26	2018-05-07	Ares Trading Sa	Process for Preparation of Glycosylated Interferon Beta
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
WO2007038619A2 (fr) *	2005-09-27	2007-04-05	Amunix, Inc.	Produits pharmaceutiques proteiques et utilisations de ceux-ci
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007040437A1 (fr) *	2005-10-03	2007-04-12	Astrazeneca Ab	Protéines de fusion ayant une demi-vie modulee dans du plasma
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (fr)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
AU2006329944A1 (en) *	2005-12-09	2007-07-05	Seattle Genetics, Inc.	Methods of using CD40 binding agents
AU2006323925B2 (en) *	2005-12-09	2012-08-02	Ares Trading S.A.	Method for purifying FSH or a FSH mutant
US8178495B2 (en)	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1976876A4 (fr) *	2005-12-22	2010-01-13	Conjuchem Biotechnologies Inc	Procédé de production de conjugués d'albumine préformés et agent thérapeutique
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
WO2007082144A2 (fr) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
EP2025762A3 (fr)	2006-01-17	2009-09-30	Health Research Inc.	Analyse de suivi hétéroduplex
EP1816201A1 (fr)	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
WO2007097961A1 (fr) *	2006-02-16	2007-08-30	Massachusetts Eye & Ear Infirmary	Utilisation d'inhibiteurs de l'azurocidine dans la prévention et le traitement d'une fuite vasculaire oculaire
WO2007103469A2 (fr)	2006-03-06	2007-09-13	Aeres Biomedical Ltd.	Anticorps anti-cd22 humanisés et leur utilisation dans un traitement oncologique, d'une transplantation et d'une maladie auto-immune
EP2738179A1 (fr)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Purification d'anticorps
DE602007007923D1 (de)	2006-04-11	2010-09-02	Csl Behring Gmbh	Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
WO2007124361A2 (fr) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	B7-h1 soluble
AU2007258609B2 (en) *	2006-06-07	2013-01-24	Human Genome Sciences, Inc.	Albumin fusion proteins
DK3896090T3 (da) *	2006-06-14	2022-03-21	Csl Behring Gmbh	Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
EP1867660A1 (fr) *	2006-06-14	2007-12-19	CSL Behring GmbH	Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) *	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP2049560B1 (fr) *	2006-07-13	2013-05-15	Novozymes Biopharma DK A/S	Procédé de fabrication de particules d'un matériau protéique
KR101193722B1 (ko)	2006-07-24	2013-01-11	바이오렉시스 파마슈티칼 코포레이션	엑센딘 융합 단백질
WO2008019036A2 (fr) *	2006-08-04	2008-02-14	Pharmathene Inc.	Butyrylcholinestérase recombinante à demi-vie longue
CA2663047A1 (fr) *	2006-09-06	2008-03-13	Phase Bioscience, Inc.	Proteines de fusion de polypeptide de type elastine therapeutique
WO2008030558A2 (fr)	2006-09-08	2008-03-13	Ambrx, Inc.	Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
AR063384A1 (es)	2006-10-25	2009-01-28	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008049920A2 (fr)	2006-10-26	2008-05-02	Novo Nordisk A/S	Variantes il-21
WO2008057459A2 (fr)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonistes de pcsk9
ES2535358T3 (es)	2006-12-12	2015-05-08	Biorexis Pharmaceutical Corporation	Bibliotecas de proteínas de fusión de transferrina
CA2673331A1 (fr)	2006-12-19	2008-06-26	Ablynx N.V.	Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
AU2007336243B2 (en)	2006-12-19	2012-07-26	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2673459C (fr) *	2006-12-22	2016-09-13	Stefan Schulte	Facteurs de coagulation modifies presentant une demi-vie in vivo prolongee
EP1935430A1 (fr) *	2006-12-22	2008-06-25	CSL Behring GmbH	Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
EP2423219B1 (fr)	2007-01-30	2015-04-29	Epivax, Inc.	Épitopes de lymphocytes T régulateurs, compositions et utilisations de ceux-ci
EP2109457B1 (fr) *	2007-02-12	2016-01-06	CSL Behring GmbH	Application thérapeutique d'inhibiteurs de sérine protéase de type kazal
EP2142217B1 (fr)	2007-03-27	2014-11-05	Merck Sharp & Dohme Corp.	Procédé de détection de pcsk9 secrétée, autogénérée
EP2703011A3 (fr)	2007-05-07	2014-03-26	MedImmune, LLC	Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
DK3072525T3 (en)	2007-05-14	2018-04-30	Astrazeneca Ab	PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
EP2738257A1 (fr)	2007-05-22	2014-06-04	Amgen Inc.	Compositions et procédés pour produire des protéines de fusion bioactives
EP1997830A1 (fr)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	Molécules à liaison spécifiques RSV et leur moyen de fabrication
AU2008293885A1 (en)	2007-07-13	2009-03-05	The John Hopkins University	B7-DC variants
AU2008275911A1 (en) *	2007-07-19	2009-01-22	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self- anchoring MEMS intrafascicular neural electrode
MX2010001684A (es) *	2007-08-15	2010-04-21	Amunix Inc	Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
PE20090993A1 (es)	2007-08-29	2009-07-08	Sanofi Aventis	Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
JP2009055838A (ja) *	2007-08-31	2009-03-19	Nipro Corp	融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
CN101868246A (zh) *	2007-09-21	2010-10-20	加利福尼亚大学董事会	被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
EP2203465A1 (fr) *	2007-10-22	2010-07-07	Merck Serono S.A.	Procédé de purification d'une protéine contenant fc
AU2008314687A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying Fc-fusion proteins
WO2009070642A1 (fr)	2007-11-28	2009-06-04	Medimmune, Llc	Formulation de protéine
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DK2245064T3 (da)	2007-12-21	2014-10-27	Medimmune Ltd	BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
US20100311072A1 (en) *	2008-01-28	2010-12-09	Bristol-Myers Squibb Company	Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
WO2009111315A2 (fr) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Méthodes de réduction de l’inflammation granulomateuse
JP5020135B2 (ja) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	携帯端末装置およびコンピュータプログラム
US9242011B2 (en)	2008-04-01	2016-01-26	Novo Nordisk A/S	Insulin albumin conjugates
AU2009235467A1 (en)	2008-04-07	2009-10-15	Ablynx Nv	Single variable domains against the Notch pathways
US9296810B2 (en)	2008-05-02	2016-03-29	Novartis Ag	Fibronectin-based binding molecules and uses thereof
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
DK2865760T3 (en) *	2008-06-24	2018-01-15	Csl Behring Gmbh	Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
US8772326B2 (en)	2008-07-10	2014-07-08	Anigion Biomedica Corp.	Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2010010119A1 (fr)	2008-07-22	2010-01-28	Ablynx Nv	Séquences d’acides aminés dirigées contre des récepteurs de désactiveurs multicibles et polypeptides
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
ES2545609T3 (es)	2008-08-25	2015-09-14	Amplimmune, Inc.	Composiciones de antagonistas de PD-1 y métodos de uso
JP2012500652A (ja) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	標的化共刺激ポリペプチドおよび癌を処置するための使用方法
KR101442323B1 (ko)	2008-09-07	2014-09-25	글라이코넥스 인코포레이티드	항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
CN102282168A (zh) *	2008-11-18	2011-12-14	梅里麦克制药股份有限公司	人血清白蛋白接头以及其结合物
EP2370593B1 (fr)	2008-11-28	2016-03-30	Emory University	Procédés pour déterminer l'efficacité d'antagonistes de pd-1
EP4209510B1 (fr)	2008-12-09	2024-01-31	F. Hoffmann-La Roche AG	Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US8748115B2 (en)	2008-12-12	2014-06-10	Merck Sharp & Dohme Corp.	PCSK9 immunoassay
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
MX2011007583A (es)	2009-01-16	2011-12-14	Teva Pharma	Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
WO2010087927A2 (fr)	2009-02-02	2010-08-05	Medimmune, Llc	Anticorps contre le virus respiratoire syncytial et procédés permettant de produire des vaccins contre le virus respirateur syncytial
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CN108530543B (zh)	2009-02-03	2023-06-23	阿穆尼克斯制药公司	延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010092135A2 (fr)	2009-02-11	2010-08-19	Novozymes Biopharma Uk Ltd.	Variants de l'albumine et leurs conjugués
EP3385279B1 (fr)	2009-03-20	2020-02-26	Amgen Inc.	Immunoglobulines porteuses et utilisations de celles-ci
EP2427486B1 (fr)	2009-05-07	2015-02-25	Novozymes Biopharma DK A/S	Procédé de purification de l'albumine
WO2010138555A2 (fr) *	2009-05-26	2010-12-02	University Of Florida Research Foundation, Inc.	Système d'expression de petits peptides dans des cellules de mammifère
EP2258398A1 (fr) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Conjugués d'albumine-peptide d'amyloide et leurs utilisations
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
JP5839597B2 (ja) *	2009-06-08	2016-01-06	アムニクスオペレーティングインコーポレイテッド	グルコース調節ポリペプチド並びにその作成及び使用方法
AU2010282340B2 (en)	2009-08-13	2016-12-22	The Johns Hopkins University	Methods of modulating immune function
WO2011020866A2 (fr)	2009-08-20	2011-02-24	Csl Behring Gmbh	Facteurs de coagulation fusionnés à de l'albumine pour l'administration non intraveineuse dans le cadre de la thérapie et du traitement prophylactique des troubles hémostatiques
CN102741275B (zh)	2009-08-24	2016-08-03	阿穆尼克斯运营公司	凝血因子ix组合物及其制备和使用方法
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US12544491B2 (en)	2009-08-24	2026-02-10	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
UY32920A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110195494A1 (en)	2009-10-02	2011-08-11	Boehringer Ingelheim International Gmbh	Dll4-binging molecules
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
AU2010303415B2 (en)	2009-10-07	2015-02-19	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2493916B1 (fr) *	2009-10-26	2016-06-08	Externautics S.p.A.	Marqueurs associés avec des tumeurs pulmonaires et leur utilisation
CN102596249A (zh)	2009-10-30	2012-07-18	默沙东公司	Ax1和ax189 pcsk9拮抗剂和变体
WO2011051327A2 (fr)	2009-10-30	2011-05-05	Novartis Ag	Petites protéines à chaîne unique de type anticorps
IN2012DN03824A (fr)	2009-10-30	2015-08-28	Merck Sharp & Dohme
CN102741280B (zh)	2009-10-30	2015-12-02	诺维信生物制药丹麦公司	白蛋白变体
WO2011051466A1 (fr)	2009-11-02	2011-05-05	Novartis Ag	Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
EP2501714A4 (fr) *	2009-11-17	2015-10-07	Univ Montreal	Hétéropeptides utiles pour réduire l'adsorption non-spécifique
WO2011069164A2 (fr) *	2009-12-06	2011-06-09	Biogen Idec Ma Inc.	Polypeptides chimériques et hybrides de facteur viii-fc, et procédés d'utilisation de ceux-ci
CN102711795A (zh)	2009-12-08	2012-10-03	泰华制药工业有限公司	用于治疗可卡因滥用的BChE白蛋白融合体
HRP20251657T1 (hr)	2009-12-14	2026-02-13	Ablynx N.V.	Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
AU2010340358B2 (en)	2009-12-21	2014-07-24	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
RU2605627C2 (ru)	2010-01-22	2016-12-27	Ново Нордиск Хелс Кеа Аг	Гормоны роста с пролонгированной эффективностью in vivo
RU2012134974A (ru)	2010-01-22	2014-02-27	Ново Нордиск Хелс Кеа Аг	Стабилизированное соединение гормона роста
WO2011092233A1 (fr)	2010-01-29	2011-08-04	Novartis Ag	Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP2547328B1 (fr) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Administration et co-administration de ligands de ccr7 en immunothérapie
US8337845B2 (en)	2010-03-03	2012-12-25	Boehringer Ingelheim International Gmbh	A-beta binding polypeptides
EP2371857A1 (fr)	2010-04-01	2011-10-05	CSL Behring GmbH	Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
CN106977608A (zh)	2010-04-09	2017-07-25	阿尔布麦狄克斯公司	白蛋白衍生物和变体
EA201291181A1 (ru)	2010-05-06	2013-05-30	Новартис Аг	Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CA2798432A1 (fr)	2010-05-06	2011-11-10	Novartis Ag	Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6)
MX2012013490A (es)	2010-05-20	2013-01-29	Ablynx Nv	Materiales biologicos relacionados con her3.
PT3552619T (pt)	2010-07-09	2025-10-23	Bioverativ Therapeutics Inc	Polipéptidos de fator ix e métodos de uso dos mesmos
EP3508573A1 (fr)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systèmes de traitement de facteur viii et procédés associés
WO2012019061A2 (fr)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Nouveaux effecteurs et leurs procédés d'utilisation
CA2807552A1 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucleiques modifies et leurs procedes d'utilisation
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
JP6017422B2 (ja)	2010-08-10	2016-11-02	エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）ＥｃｏｌｅＰｏｌｙｔｅｃｈｎｉｑｕｅＦｅｄｅｒａｌｅｄｅＬａｕｓａｎｎｅ（ＥＰＦＬ）	赤血球結合療法
SG187908A1 (en)	2010-08-20	2013-03-28	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
US20130224191A1 (en)	2010-08-27	2013-08-29	Robert A. Stull	Notum protein modulators and methods of use
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
WO2012031273A2 (fr)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Nouveaux modulateurs et leurs procédés d'utilisation
EP2619226B1 (fr)	2010-09-22	2018-09-12	Amgen Inc.	Immunoglobulines porteuses et leur utilisation
JP2014502252A (ja)	2010-09-28	2014-01-30	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	作用持続時間が増した改変ポリペプチド
ES3005233T3 (en)	2010-10-01	2025-03-14	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
US20130225496A1 (en)	2010-11-01	2013-08-29	Novozymes Biopharma Dk A/S	Albumin Variants
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
EA037063B1 (ru)	2010-11-08	2021-02-01	Аблинкс Н.В.	Cxcr2-связывающие полипептиды
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
TWI655210B (zh)	2010-12-08	2019-04-01	艾伯維史坦森特瑞斯有限責任公司	新穎調節劑及其使用方法
CA2823286C (fr)	2010-12-28	2020-01-28	Dainippon Sumitomo Pharma Co., Ltd.	Medicament de diagnostic et procede de diagnostic pour la maladie d'alzheimer
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
WO2012117336A2 (fr)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino	Molécules induisant l'apoptose et leurs utilisations
ES2676878T3 (es)	2011-03-03	2018-07-25	Zymeworks Inc.	Diseño de armazón de heteromultímero multivalente y constructos
DK2683397T3 (en)	2011-03-09	2017-09-18	Csl Behring Gmbh	FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
EP2497489A1 (fr)	2011-03-09	2012-09-12	CSL Behring GmbH	Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes
US9340590B2 (en)	2011-03-16	2016-05-17	Amgen Inc.	Potent and selective inhibitors of NaV1.3 and NaV1.7
TWI719112B (zh)	2011-03-16	2021-02-21	賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
WO2012135500A1 (fr)	2011-03-29	2012-10-04	The General Hospital Corporation	Protéines pliées de type thioredoxine manipulées
PE20140964A1 (es)	2011-03-30	2014-08-17	Boehringer Ingelheim Int	Antidotos anticoagulantes
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9409987B2 (en)	2011-04-15	2016-08-09	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (fr) *	2011-04-22	2015-08-12	Sysmex Corporation	Procédé de détection électrochimique d'analytes
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
MX353816B (es) *	2011-05-05	2018-01-30	Albumedix As	Variantes de albumina.
WO2012170742A2 (fr)	2011-06-07	2012-12-13	University Of Hawaii	Traitement et prévention du cancer avec des antagonistes du hmgb1
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
CA2838833A1 (fr)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Composes pro-coagulants et leurs procedes d'utilisation
WO2012172495A1 (fr)	2011-06-14	2012-12-20	Novartis Ag	Compositions et procédés de ciblage du tem8 par des anticorps
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
SG10201601621PA (en)	2011-06-28	2016-04-28	Inhibrx Llc	Serpin fusion polypeptides and methods of use thereof
US9382305B2 (en)	2011-07-01	2016-07-05	Bayer Intellectual Property Gmbh	Relaxin fusion polypeptides and uses thereof
BR112014000042A2 (pt)	2011-07-05	2017-02-21	Novozymes Biopharma Dk As	composição, meio de cultura celular, uso de uma composição, e, método para cultivar células
WO2013007563A1 (fr)	2011-07-08	2013-01-17	Bayer Intellectual Property Gmbh	Protéines de fusion libérant de la relaxine et leurs utilisations
ES2732475T3 (es)	2011-07-08	2019-11-22	Aegerion Pharmaceuticals Inc	Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
BR112014001274A2 (pt)	2011-07-18	2017-04-18	Arts Biologics As	composto de hormônio luteinizante, e, composição farmacêutica
JP6253578B2 (ja)	2011-07-22	2017-12-27	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
AU2012332593B2 (en)	2011-11-01	2016-11-17	Bionomics, Inc.	Anti-GPR49 antibodies
EP2773664A1 (fr)	2011-11-01	2014-09-10	Bionomics, Inc.	Anticorps anti-gpr49
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
EP2773373B1 (fr)	2011-11-01	2018-08-22	Bionomics, Inc.	Procédés de blocage de la croissance des cellules souches cancéreuses
JP2014533247A (ja)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	抗体および癌を治療する方法
KR20140091031A (ko)	2011-11-04	2014-07-18	노파르티스 아게	저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
PL2773671T3 (pl)	2011-11-04	2022-01-24	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
HK1200842A1 (en)	2011-11-18	2015-08-14	Albumedix Ltd	Proteins with improved half-life and other properties
JP2015500829A (ja)	2011-12-05	2015-01-08	ノバルティスアーゲー	上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
KR102083957B1 (ko)	2011-12-05	2020-03-04	노파르티스 아게	표피 성장 인자 수용체 3 (her3)에 대한 항체
JP2015501844A (ja)	2011-12-16	2015-01-19	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
ES2728278T3 (es)	2011-12-21	2019-10-23	Novartis Ag	Composiciones que comprenden anticuerpos dirigidos al factor P y C5
CN104080474B (zh)	2011-12-22	2016-04-27	德国杰特贝林生物制品有限公司	C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
EP2804623B1 (fr)	2012-01-12	2019-08-07	Bioverativ Therapeutics Inc.	Facteur viii chimérique et polypeptides et leurs utilisations
EP2623110A1 (fr)	2012-01-31	2013-08-07	CSL Behring GmbH	Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
WO2013120939A1 (fr) *	2012-02-15	2013-08-22	Csl Behring Gmbh	Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
LT3564260T (lt)	2012-02-15	2023-01-10	Bioverativ Therapeutics Inc.	Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (fr)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Protéines de facteur viii de recombinaison
NZ722352A (en)	2012-02-15	2022-05-27	Ecole Polytechnique Fed Lausanne Epfl	Erythrocyte-binding therapeutics
RU2014138474A (ru)	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
CN104245735B (zh)	2012-02-27	2018-02-23	勃林格殷格翰国际有限公司	Cx3cr1结合多肽
MX2014010278A (es)	2012-03-16	2015-03-05	Novozymes Biopharma Dk As	Variantes de albumina.
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US9550819B2 (en)	2012-03-27	2017-01-24	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
WO2013151663A1 (fr)	2012-04-02	2013-10-10	modeRNA Therapeutics	Polynucléotides modifiés pour la production de protéines membranaires
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
WO2013158273A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158279A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de purification de protéines pour réduire des espèces acides
CN110078827A (zh) *	2012-04-27	2019-08-02	西托姆克斯治疗公司	结合表皮生长因子受体的可活化的抗体其使用方法
WO2013166290A1 (fr)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	Dosage de biomarqueurs de p21
WO2013167153A1 (fr)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Anticorps utiles dans le diagnostic du cancer
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
JP6351572B2 (ja)	2012-05-10	2018-07-04	ザイムワークス，インコーポレイテッド	Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (fr)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarqueurs destinés à prédire la réponse à une thérapie par un agoniste du récepteur tweak (tweakr)
PT2854548T (pt)	2012-05-30	2018-12-06	Bayer Cropscience Ag	Composição compreendendo um agente de controlo biológico e um fungicida selecionado a partir de metalaxilo e metalaxil-m
NZ701724A (en)	2012-05-30	2016-11-25	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
EP3300603A3 (fr)	2012-05-30	2018-06-27	Bayer CropScience Aktiengesellschaft	Compositions comprenant un agent de contrôle biologique et un fongicide
US9386773B2 (en)	2012-05-30	2016-07-12	Bayer Cropscience Ag	Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex I or II
AU2013269663B2 (en)	2012-05-30	2016-12-01	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
WO2013178658A1 (fr)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprenant un agent de lutte biologique et un insecticide
AU2013269660B2 (en)	2012-05-30	2016-07-07	Bayer Cropscience Ag	Compositiions comprising a biological control agent and an insecticide
PT2854547T (pt)	2012-05-30	2018-11-16	Bayer Cropscience Ag	Composição que compreende um agente de controlo biológico e trifloxistrobina
BR122019010584B1 (pt)	2012-05-30	2020-06-30	Bayer Cropscience Ag.	composição que compreende um agente de controle biológico e um fungicida, seus usos, semente resistente a patógeno, método para reduzir os danos totais em plantas e em partes de plantas, e kit de partes
AR091201A1 (es)	2012-05-30	2015-01-21	Bayer Cropscience Ag	Composicion que comprende un agente de control biologico y un fungicida
MX356530B (es)	2012-05-30	2018-06-01	Bayer Cropscience Ag	Composicion que comprende un agente de control biologico y un fungicida seleccionado de inhibidores de la biosintesis de aminoacidos o proteinas, inhibidores de la produccion de atp e inhibidores de la sintesis de la pared celular.
WO2013178663A1 (fr)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprenant un agent de lutte biologique et un insecticide
EP2863940A4 (fr)	2012-06-08	2016-08-10	Biogen Ma Inc	Facteurs de coagulation chimériques
AU2013270682A1 (en)	2012-06-08	2014-12-11	Biogen Ma Inc.	Procoagulant compounds
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	이듀로네이트-2-설파타제의 정제
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN110054699A (zh)	2012-07-11	2019-07-26	比奥贝拉蒂治疗公司	具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
AU2013289881B2 (en)	2012-07-13	2018-01-18	Zymeworks Bc Inc.	Multivalent heteromultimer scaffold design and constructs
WO2014036520A1 (fr)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Polythérapies comprenant des agents anti-erbb3
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
KR20150043523A (ko)	2012-09-02	2015-04-22	애브비 인코포레이티드	단백질 불균일성의 제어 방법
US10391152B2 (en)	2012-10-18	2019-08-27	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
WO2014072481A1 (fr)	2012-11-08	2014-05-15	Novozymes Biopharma Dk A/S	Variants d'albumine
CN105073776B (zh)	2012-11-13	2019-04-12	拜恩科技股份公司	用于治疗表达紧密连接蛋白的癌症疾病的制剂
ES2921623T3 (es)	2012-11-26	2022-08-30	Modernatx Inc	ARN modificado terminalmente
WO2014084859A1 (fr)	2012-11-30	2014-06-05	Novartis Ag	Molécules et procédés pour la modulation d'activités de tmem16a
WO2014089111A1 (fr)	2012-12-05	2014-06-12	Novartis Ag	Compositions et procédés pour des anticorps ciblant epo
JP6426107B2 (ja)	2012-12-20	2018-11-21	アムジエン・インコーポレーテツド	Ａｐｊ受容体アゴニストおよびその使用
AR094481A1 (es)	2013-01-15	2015-08-05	Teva Pharma	Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos
KR101503907B1 (ko) *	2013-01-17	2015-03-20	서울대학교산학협력단	흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
EP2950807B1 (fr)	2013-01-30	2018-03-28	NGM Biopharmaceuticals, Inc.	Compositions et procédés à utiliser pour le traitement de troubles métaboliques
TWI682941B (zh)	2013-02-01	2020-01-21	美商再生元醫藥公司	含嵌合恆定區之抗體
BR112015018676A2 (pt)	2013-02-11	2017-07-18	Bayer Cropscience Lp	composições que compreendem gougerotina e um agente de controle biológico
FI3889173T3 (fi)	2013-02-15	2023-10-02	Bioverativ Therapeutics Inc	Optimoitu tekijä viii:n geeni
WO2014125082A1 (fr)	2013-02-16	2014-08-21	Novozymes Biopharma Dk A/S	Modèle pharmacocinétique animal
WO2014131865A1 (fr)	2013-02-28	2014-09-04	Csl Behring Gmbh	Agent thérapeutique pour l'embolie de liquide amniotique
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
KR102403299B1 (ko)	2013-03-08	2022-06-03	체에스엘 베링 게엠베하	원격 허혈-재관류 손상의 치료 및 예방
AU2014249045A1 (en)	2013-03-11	2015-10-29	University Of Florida Research Foundation, Inc.	Delivery of CARD protein as therapy for occular inflammation
WO2014165277A2 (fr)	2013-03-12	2014-10-09	Amgen Inc.	Inhibiteurs sélectifs et puissants de nav1.7
SG11201507230PA (en)	2013-03-12	2015-10-29	Abbvie Inc	Human antibodies that bind human tnf-alpha and methods of preparing the same
EP2968587A2 (fr)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
US20160024181A1 (en) *	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
WO2014151878A2 (fr)	2013-03-14	2014-09-25	Abbvie Inc.	Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
JP2016514130A (ja)	2013-03-14	2016-05-19	ノバルティスアーゲー	Ｎｏｔｃｈ３に対する抗体
TWI828269B (zh)	2013-03-15	2024-01-01	美商百歐維拉提夫治療公司	因子ix多肽調配物
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP3473272A1 (fr)	2013-03-29	2019-04-24	Alexion Pharmaceuticals, Inc.	Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire
EP2981282B1 (fr) *	2013-04-05	2020-11-04	Novo Nordisk Health Care AG	Formulation d'un composé d'hormone de croissance
ES2657291T3 (es)	2013-04-22	2018-03-02	Csl Ltd.	Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es)	2013-06-21	2015-01-30	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
MX2015016567A (es)	2013-06-28	2016-03-31	Biogen Ma Inc	Enlazador escindible por trombina con xten y usos del mismo.
JP2017501968A (ja)	2013-06-28	2017-01-19	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
CN104342420B (zh) *	2013-07-30	2017-09-15	惠觅宙	一种重组长效人透明质酸酶、其编码基因、生产方法及应用
US20160311885A1 (en)	2013-08-14	2016-10-27	Biogen Ma Inc.	Recombinant factor viii proteins
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CA2920835A1 (fr)	2013-08-20	2015-02-26	Anutra Medical, Inc.	Systeme de remplissage de seringue et procede associe
CA2922529A1 (fr)	2013-08-28	2015-03-05	Stemcentrx, Inc.	Nouveaux modulateurs sez6 et procedes d'utilisation
PE20160674A1 (es)	2013-08-28	2016-07-21	Stemcentrx Inc	Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EP3048899B1 (fr)	2013-09-25	2021-09-08	Bioverativ Therapeutics Inc.	Procédés d'inactivation de virus sur colonne
CN103468662A (zh) *	2013-09-29	2013-12-25	惠觅宙	一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
WO2015048744A2 (fr)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
EP3470081A1 (fr)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3052640A2 (fr)	2013-10-04	2016-08-10	AbbVie Inc.	Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
WO2015057403A2 (fr) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions et méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9540440B2 (en)	2013-10-30	2017-01-10	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SI3063275T1 (sl)	2013-10-31	2020-02-28	Resolve Therapeutics, Llc	Terapevtske fuzije nukleaza-albumin in postopki
JP6306700B2 (ja) *	2013-11-01	2018-04-04	ユニバーシティオブオスロＵｎｉｖｅｒｓｉｔｙｏｆＯｓｌｏ	アルブミン改変体及びその使用
WO2015070014A1 (fr)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Composé de fusion procoagulant
WO2015073884A2 (fr)	2013-11-15	2015-05-21	Abbvie, Inc.	Compositions de protéines de liaison génétiquement glycomodifiées
WO2015089283A1 (fr)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
US11135269B2 (en) *	2013-12-11	2021-10-05	The General Hospital Corporation	Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
ES2902835T3 (es)	2014-01-09	2022-03-30	Hadasit Med Res Service	Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
SG11201605242YA (en)	2014-01-10	2016-07-28	Biogen Ma Inc	Factor viii chimeric proteins and uses thereof
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
KR20240154672A (ko)	2014-02-21	2024-10-25	에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘)	글리코타겟팅 치료제
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
WO2015138628A1 (fr)	2014-03-11	2015-09-17	University Of Florida Research Foundation, Inc.	Utilisation de la protéine m013 exprimée par un vecteur aav comme agent thérapeutique anti-inflammatoire
US20170107294A1 (en) *	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (fr)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprenant de la ningnanmycine et un agent de lutte biologique
WO2015164615A1 (fr)	2014-04-24	2015-10-29	University Of Oslo	Anticorps anti-gluten et leurs utilisations
KR20170003611A (ko)	2014-05-02	2017-01-09	세레니스 쎄라퓨틱스 홀딩 에스에이	Ｈｄｌ 요법 마커
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (zh) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	一种融合蛋白、其制备方法及其应用
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
EP3155002B1 (fr)	2014-06-10	2019-11-27	Amgen Inc.	Polypeptides d'apéline
CN106456778A (zh)	2014-06-18	2017-02-22	德国杰特贝林生物制品有限公司	在神经创伤性病患中使用因子xii抑制剂进行治疗
US20170204149A1 (en)	2014-06-23	2017-07-20	Novartis Ag	Hsa-gdf-15 fusion polypeptide and use thereof
CN106459222A (zh)	2014-06-24	2017-02-22	诺和诺德股份有限公司	Mic‑1融合蛋白及其用途
WO2016004113A1 (fr)	2014-06-30	2016-01-07	Biogen Ma Inc.	Gène du facteur ix optimisé
EP3171896A4 (fr)	2014-07-23	2018-03-21	Mayo Foundation for Medical Education and Research	Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
TN2016000578A1 (en)	2014-07-30	2018-04-04	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders
SG10201805646WA (en)	2014-08-07	2018-08-30	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (fr)	2014-08-07	2016-02-11	Novartis Ag	Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
EP3182988A4 (fr) *	2014-08-22	2018-05-23	National Cheng Kung University	Variants de désintégrine et utilisations pharmaceutiques de ceux-ci
BR112017005378B1 (pt)	2014-09-17	2022-07-12	Basf Corporation	Composição para acentuar o crescimento vegetal e método relacionado
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AP2017009826A0 (en)	2014-09-26	2017-03-31	Bayer Pharma AG	Stabilized adrenomedullin derivatives and use thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
BR112017007765B1 (pt)	2014-10-14	2023-10-03	Halozyme, Inc	Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
EP3212226B1 (fr)	2014-10-31	2020-03-18	NGM Biopharmaceuticals, Inc.	Compositions et leurs méthodes d'utilisation pour le traitement de troubles métaboliques
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
RU2694820C9 (ru) *	2014-12-23	2019-08-12	Мерц Фарма Гмбх Унд Ко. Кгаа	Контейнер, предварительно заполненный ботулиновым токсином
WO2016161010A2 (fr)	2015-03-30	2016-10-06	Regeneron Pharmaceuticals, Inc.	Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
JP2016204292A (ja) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
PL3288965T3 (pl) *	2015-04-29	2019-11-29	Mediolanum Farm S P A	Rozpuszczalny chimeryczny receptor interleukiny-10 i jego zastosowanie terapeutyczne
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (fr) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Méthodes de traitement d'états médiés par la substance p
EA201792561A1 (ru)	2015-06-05	2018-04-30	Новартис Аг	Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
WO2016201202A1 (fr) *	2015-06-11	2016-12-15	Attwill Medical Solutions Inc.	Dispositifs médicaux, systèmes et procédés utilisant des compositions à base d'antithrombine-héparine
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
US11020455B2 (en) *	2015-07-30	2021-06-01	Endor Technologies, S.L	Colony stimulating factor for use in pancreatic or colon cancer treatment
IL257231B (en)	2015-08-03	2022-09-01	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same
WO2017021893A1 (fr)	2015-08-03	2017-02-09	Novartis Ag	Méthode de traitement des troubles associés au fgf21
US12221615B2 (en)	2015-08-06	2025-02-11	The Trustees Of The University Of Pennsylvania	GLP-1 and use thereof in compositions for treating metabolic diseases
WO2017029407A1 (fr)	2015-08-20	2017-02-23	Albumedix A/S	Variants de l'albumine et leurs conjugués
PT3348635T (pt)	2015-09-08	2021-03-15	Japan Chem Res	Novo mutante de albumina do soro humano
US10000561B2 (en)	2015-09-09	2018-06-19	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
KR20180042433A (ko)	2015-09-09	2018-04-25	노파르티스 아게	흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
KR102739782B1 (ko) *	2015-09-11	2024-12-09	더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티	생물학적으로 관련된 직교 사이토카인/수용체 쌍
KR102777500B1 (ko)	2015-09-23	2025-03-11	리제너론 파아마슈티컬스, 인크.	최적화된 항-cd3 이중특이적 항체 및 이의 용도
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
KR102802241B1 (ko)	2015-12-04	2025-05-07	베링거 인겔하임 인터내셔날 게엠베하	종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CA3008102A1 (fr)	2015-12-18	2017-06-22	Novartis Ag	Anticorps ciblant cd32b et leurs procedes d'utilisation associes
CN108367053A (zh)	2015-12-22	2018-08-03	诺华股份有限公司	使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
HK1257518A1 (zh)	2016-01-11	2019-10-25	Novartis Ag	针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
EP3405492B1 (fr)	2016-01-21	2020-10-21	Novartis AG	Molécules multispécifiques ciblant cll-1
KR20180118659A (ko)	2016-02-01	2018-10-31	바이오버라티브 테라퓨틱스 인크.	최적화된 viii 인자 유전자
WO2017159540A1 (fr) *	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	Protéine de fusion albumine sérique-hormone de croissance 20k
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
WO2017172260A1 (fr)	2016-03-31	2017-10-05	Ngm Bioparmaceuticals, Inc.	Protéines de liaison et leurs procédés d'utilisation
AU2017247004B2 (en)	2016-04-06	2022-07-07	Csl Limited	Method of treating atherosclerosis
CN109071647B (zh)	2016-04-27	2022-11-22	诺华股份有限公司	抗生长分化因子15的抗体及其用途
UA127200C2 (uk)	2016-05-18	2023-06-07	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Молекула антитіла до pd1
MA45113A (fr)	2016-05-24	2019-04-10	Novo Nordisk As	Composés mic-1 et leur utilisation
CA3027651A1 (fr)	2016-06-15	2017-12-21	Novartis Ag	Methodes de traitement de maladie a l'aide d'inhibiteurs de la proteine morphogenetique osseuse 6 (bmp6)
KR102446476B1 (ko) *	2016-07-08	2022-10-19	체에스엘 베링 렝나우 아게	사람에서의 장기-작용성 인자 ix의 피하 투여
WO2018014260A1 (fr)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja)	2016-08-23	2019-11-28	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
WO2018068201A1 (fr)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Anticorps à domaine unique et ses variants contre ctla-4
JP2020500306A (ja)	2016-11-04	2020-01-09	オーフスウニベルシテット	新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
EP3541407A1 (fr) *	2016-11-18	2019-09-25	Universitat de Barcelona	Polythérapie à base de cd6 et d'imipénem pour le traitement de maladies infectieuses et de processus inflammatoires associés
WO2018096396A1 (fr)	2016-11-22	2018-05-31	University Of Oslo	Variants d'albumine et leurs utilisations
JP2019536794A (ja)	2016-12-02	2019-12-19	バイオベラティブセラピューティクスインコーポレイテッド	凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2018112362A1 (fr)	2016-12-16	2018-06-21	Biogen Ma Inc.	Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
EP3360898A1 (fr)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
US20200231701A1 (en)	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
BR112019012667A2 (pt)	2016-12-23	2020-02-11	Novartis Ag	Anticorpos do fator xi e métodos de uso
CA3048479A1 (fr)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Edition genique de pcsk9
WO2018132768A1 (fr)	2017-01-13	2018-07-19	Sanna Pietro P	Procédés et compositions pour le traitement de l'hyperactivité hpa
WO2018144623A1 (fr)	2017-01-31	2018-08-09	Bioverativ Therapeutics Inc.	Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
EP3580237B1 (fr)	2017-02-08	2025-05-14	Novartis AG	Anticorps mimétiques du fgf21 et leurs utilisations
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
MA50141A (fr)	2017-04-20	2020-07-29	Novo Nordisk As	Procédés de purification de protéines de fusion d'albumine
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
CN110662762A (zh)	2017-05-24	2020-01-07	诺华股份有限公司	抗体细胞因子移植蛋白和用于治疗癌症的方法
TWI887192B (zh)	2017-05-31	2025-06-21	比利時商艾伯林克斯公司	拮抗腫瘤細胞中wnt訊息傳導之多肽
WO2018229715A1 (fr)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
EP3638296A1 (fr)	2017-06-16	2020-04-22	The University Of Chicago	Compositions et procédés d'induction d'une tolérance immunitaire
JP2020525498A (ja)	2017-06-29	2020-08-27	ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト	血友病の予防的処置のための第ｉｘ因子およびヒトアルブミンを含む融合タンパク質に関する２１日の投与計画およびその方法
FI3661562T3 (fi)	2017-08-04	2024-12-09	Amgen Inc	Cys-mab:ien konjugointimenetelmä
BR112020002394A2 (pt)	2017-08-09	2020-07-28	Bioverativ Therapeutics Inc.	moléculas de ácidos nucleicos e usos das mesmas
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
CA3075686A1 (fr)	2017-09-15	2019-03-21	Cedars-Sinai Medical Center	Procedes pour ameliorer la fonction d'organes chez des patients ayant subi une transplantation d'organe
US11466073B2 (en)	2017-10-18	2022-10-11	Csl Limited	Human serum albumin variants and uses thereof
WO2019081983A1 (fr)	2017-10-25	2019-05-02	Novartis Ag	Anticorps ciblant cd32b et leurs procédés d'utilisation
AU2018382222B2 (en)	2017-12-15	2025-09-04	Csl Limited	Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (fr)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Triacorps, son procédé de préparation et son utilisation
TW201930358A (zh)	2017-12-28	2019-08-01	大陸商南京傳奇生物科技有限公司	針對ｔｉｇｉｔ之單域抗體及其變異體
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
KR102839330B1 (ko)	2018-01-15	2025-07-30	난징 레전드 바이오테크 씨오., 엘티디.	Pd-1에 대한 단일-도메인 항체 및 이의 변이체
AU2019215063B2 (en)	2018-02-01	2025-10-16	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing Factor VIII
FI3765525T3 (fi)	2018-03-13	2023-10-16	Zymeworks Bc Inc	Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
RS64455B1 (sr) *	2018-03-13	2023-09-29	Sepsia Therapeutics S L	Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa
KR102824112B1 (ko)	2018-03-28	2025-06-24	브리스톨-마이어스 스큅 컴퍼니	인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
JP7346790B2 (ja)	2018-03-30	2023-09-20	ナンジンレジェンドバイオテックカンパニー，リミテッド	Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
KR102119197B1 (ko) *	2018-04-23	2020-06-05	주식회사 엘베이스	세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
SG11202011078VA (en)	2018-05-09	2020-12-30	Univ Chicago	Compositions and methods concerning immune tolerance
CN113840832A (zh)	2018-05-14	2021-12-24	狼人治疗公司	可活化白介素-2多肽及其使用方法
WO2019222294A1 (fr)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Polypeptides de cytokine activables et leurs procédés d'utilisation
US20210130430A1 (en)	2018-05-14	2021-05-06	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
SI3793588T1 (sl)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Postopki zdravljenja hemofilije A
EP3569618A1 (fr)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonisation d'anticorps cd73
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AU2019277029C1 (en)	2018-06-01	2024-01-04	Novartis Ag	Binding molecules against BCMA and uses thereof
EP3807321A4 (fr)	2018-06-18	2022-03-02	Anwita Biosciences, Inc.	Constructions anti-mésothéline et utilisations associées
AU2019297327A1 (en)	2018-07-03	2021-02-18	Bristol-Myers Squibb Company	FGF21 formulations
KR102925832B1 (ko)	2018-08-09	2026-02-11	바이오버라티브 테라퓨틱스 인크.	핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
PT3844189T (pt)	2018-08-31	2025-01-29	Regeneron Pharma	Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
US20220056115A1 (en) *	2018-09-17	2022-02-24	Kyoto University	Administration of an anti-c5 agent for treatment of hepatic injury or failure
MX2021003543A (es)	2018-09-27	2021-06-23	Xilio Dev Inc	Polipeptidos de citocinas enmascaradas.
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
CA3117961A1 (fr) *	2018-10-29	2020-05-07	Spin Therapeutics, Llc	Compositions et methodes pour les dereglements de l'alpha-1 antitrypsine
CA3116412A1 (fr)	2018-10-31	2020-05-07	Humanigen, Inc.	Substances et methodes pour le traitement du cancer
WO2020092839A1 (fr)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Méthodes et matériaux de traitement du cancer
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
JP2022513626A (ja)	2018-11-26	2022-02-09	ノバルティスアーゲー	Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
BR112021010047A2 (pt)	2018-12-06	2021-08-24	Bioverativ Therapeutics Inc.	Uso de vetores lentivirais expressando o fator ix
JP2022521353A (ja)	2019-03-22	2022-04-06	リフレクションファーマシューティカルズ，インコーポレイテッド	Ｖｅｇｆのためのｄ－ペプチド性化合物
WO2020198075A2 (fr)	2019-03-22	2020-10-01	Reflexion Pharmaceuticals, Inc.	Composés d-peptidiques multivalents pour protéines cibles
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
CN114026085A (zh)	2019-04-11	2022-02-08	安吉昂生物医药公司	(e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
KR20220023988A (ko)	2019-05-14	2022-03-03	웨어울프 세라퓨틱스, 인크.	분리 모이어티 및 이의 사용 방법
UY38701A (es)	2019-05-21	2020-12-31	Novartis Ag	Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
WO2020236797A1 (fr)	2019-05-21	2020-11-26	Novartis Ag	Domaines de cd58 variants et leurs utilisations
JP7784898B2 (ja)	2019-05-24	2025-12-12	サノフイ	全身性硬化症を治療するための方法
EP3986918A1 (fr)	2019-06-18	2022-04-27	Bayer Aktiengesellschaft	Analogues d'adrénomédulline pour stabilisation à long terme et leur utilisation
IL267614A (en)	2019-06-24	2019-09-26	Lotem Michal	Nucleic acids to modulate SLAMF6 isoforms
CN119285791A (zh)	2019-09-06	2025-01-10	诺华股份有限公司	治疗性融合蛋白
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US12403164B2 (en)	2019-09-30	2025-09-02	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
JP2021066730A (ja)	2019-10-17	2021-04-30	Ｊｃｒファーマ株式会社	血清アルブミンと成長ホルモンの融合蛋白質の製造方法
CN114728043B (zh)	2019-10-30	2024-04-16	Jcr制药股份有限公司	含有血清白蛋白与生长激素的融合蛋白的水性药物组合物
BR112022009110A2 (pt)	2019-11-14	2022-07-26	Werewolf Therapeutics Inc	Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021111143A1 (fr)	2019-12-04	2021-06-10	Albumedix Limited	Procédés et compositions produites par ceux-ci
KR20220127249A (ko)	2019-12-13	2022-09-19	신테카인, 인크.	Il-2 오르토로그 및 사용 방법
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
US12358963B2 (en)	2019-12-24	2025-07-15	Juvena Therapeutics, Inc.	Regenerative polypeptides and uses thereof
CA3167336A1 (fr)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Inhibiteurs de la kallicreine plasmatique et leurs utilisations pour traiter une crise d'angio-deme hereditaire pediatrique
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
GB2613457B (en)	2020-04-09	2023-12-06	Verve Therapeutics Inc	Base editing of angptl3 and methods of using same for treatment of disease
CA3180665A1 (fr)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Molecules de liaison pour le traitement du cancer
IL299048A (en)	2020-06-14	2023-02-01	Vertex Pharma	Variants of complement factor - 1 fusion structures and preparations containing them and their uses
KR20230074703A (ko)	2020-06-24	2023-05-31	바이오버라티브 테라퓨틱스 인크.	유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
JP7633397B2 (ja)	2020-10-21	2025-02-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	眼の疾患の処置のための二重特異性抗ＶＥＧＦ及び抗ＴｒｋＢ結合分子
JP2023547479A (ja) *	2020-10-30	2023-11-10	シェンチェン、プロトゲン、リミテッド	疾患の治療におけるヒト血清アルブミンの使用
EP4240491A1 (fr)	2020-11-06	2023-09-13	Novartis AG	Molécules de liaison à cd19 et utilisations associées
JP2023553323A (ja)	2020-11-25	2023-12-21	エクシリオデベロップメント，インコーポレイテッド	腫瘍特異的に切断可能なリンカー
CN114478800B (zh) *	2021-02-05	2022-10-11	华南理工大学	基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN117321076A (zh)	2021-02-19	2023-12-29	美国卫生及公众服务部代表	中和SARS-CoV-2的单结构域抗体
TW202317625A (zh)	2021-06-17	2023-05-01	德商百靈佳殷格翰國際股份有限公司	新穎三特異性結合分子
CA3223707A1 (fr)	2021-06-21	2022-12-29	Hanadie Yousef	Polypeptides regenerateurs et leurs utilisations
CN114133458B (zh) *	2021-12-08	2023-11-14	福州大学	一种在人血清白蛋白内部融合多肽的方法
WO2023147053A2 (fr) *	2022-01-28	2023-08-03	Sigilon Therapeutics, Inc.	Thérapies pour la mucopolysaccharidose de type 6
WO2023209568A1 (fr)	2022-04-26	2023-11-02	Novartis Ag	Anticorps multispécifiques ciblant il-13 et il-18
EP4554677A1 (fr)	2022-07-15	2025-05-21	Boehringer Ingelheim International GmbH	Molécules de liaison pour le traitement du cancer
CN119546339A (zh)	2022-07-15	2025-02-28	丹尼斯科美国公司	用于产生单克隆抗体的方法
WO2024083843A1 (fr)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
WO2024130158A1 (fr)	2022-12-16	2024-06-20	Modernatx, Inc.	Nanoparticules lipidiques et polynucléotides codant l'interleukine-22 à demi-vie sérique étendue pour le traitement d'une maladie métabolique
TW202440624A (zh) *	2022-12-20	2024-10-16	澳大利亞商杰特創新股份有限公司	FcRn拮抗劑及其用途
EP4389762A1 (fr)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibiteurs de l'activité de dux4 et leur utilisation en thérapie.
WO2024178305A1 (fr)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions de protéines de fusion il-15 codées par arnm et leurs méthodes d'utilisation pour le traitement du cancer
EP4442251A1 (fr)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations et leurs utilisations
WO2025034806A1 (fr)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Anticorps à domaine unique et variants de ceux-ci ciblant la protéine d'activation des fibroblastes
WO2025072888A2 (fr)	2023-09-28	2025-04-03	Novavax, Inc.	Anticorps de spicule (s) anti-sars-cov-2 et leur utilisation dans le traitement du covid-19
EP4703468A1 (fr)	2024-08-29	2026-03-04	Sartorius Albumedix Limited	Procédés et utilisations
WO2026058155A1 (fr)	2024-09-11	2026-03-19	Novartis Ag	Anticorps ciblant il-31
WO2026074121A1 (fr)	2024-10-02	2026-04-09	Sartorius Albumedix Limited	Formulations d'albumine et leurs utilisations

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (de) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
CY1346A (en)	1980-01-08	1987-01-16	Biogen Nv	Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides
DE3177213D1 (de)	1980-04-03	1990-10-18	Biogen Inc	Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
DE3023787A1 (de)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
FR2490675B1 (fr)	1980-09-25	1985-11-15	Genentech Inc	Production microbienne d'interferon de fibroplaste humain
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
DE3273787D1 (en)	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en)	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
CA1204682A (fr)	1981-06-19	1986-05-20	Saran A. Narang	Adapteurs, synthese et clonage des genes proinsuliniques
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (fr)	1981-11-12	1984-08-08	The Upjohn Company	Nucléotides basés sur l'albumine, leur réplication et utilisation, et plasmides à utiliser à cet effet
EP0091527A3 (fr)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Séquences d'ADN, molécules d'ADN recombinant et procédé de préparation de polypeptides du genre de sérumalbumine humaine
JPS58107298A (ja)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
IT1167610B (it)	1982-01-19	1987-05-13	Cetus Corp	Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
EP0091539B2 (fr)	1982-03-31	1996-11-27	Ajinomoto Co., Inc.	Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules
CA1341562C (fr)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene codant pour un polypeptide ayant une activite interleukine 2, adn recombinant portant ledit gene, lignees cellulaires possedant ledit adn recombinant et procede pour la preparation d'interleukine 2 en utilisant lesdites cellules
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (fr)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipides et composés tensio-actifs en phase aqueuse
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
JPS5945835U (ja)	1982-09-16	1984-03-27	株式会社東芝	回路しや断器の消弧装置
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
DE3382547D1 (de)	1983-01-12	1992-05-27	Chiron Corp	Sekretorische expression in eukaryoten.
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
DK172738B1 (da)	1983-04-07	1999-06-21	Chiron Corp	Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1984004330A1 (fr)	1983-04-22	1984-11-08	Amgen	Secretion de polypeptides exogenes a partir de levure
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
CA1196863A (fr) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Composes d'insuline injectable a liberation lente
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	雑種制御領域
ATE159858T1 (de)	1983-09-26	1997-11-15	Ehrenfeld Udo	Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
JPS60115528A (ja)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (ja)	1983-12-26	1985-07-20	Suntory Ltd	ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it)	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
CA1213537A (fr)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Methode d'expression de polypeptides
FR2564106B1 (fr) *	1984-05-09	1988-04-22	Transgene Sa	Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da) *	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (fr)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Transformateur et son utilisation
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en) *	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (da)	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
FR2579224B1 (fr)	1985-03-25	1987-05-22	Genetica	Procede de preparation microbiologique de la serum-albumine humaine
US4751180A (en) *	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
CA1260858A (fr)	1985-03-28	1989-09-26	Lawrence S. Cousens	Expression a l'aide de genes fusionnes pour l'obtention de proteines
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
AU5890286A (en)	1985-06-17	1986-12-24	Genex Corp.	Cloned human serum albumin gene
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (ja)	1985-10-04	1994-03-16	中外製薬株式会社	白血球減少症治療剤
JPS6296086A (ja)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	複合プラスミド
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
EP0247091B1 (fr)	1985-11-01	1993-09-29	Xoma Corporation	Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
CA1295563C (fr)	1985-11-01	1992-02-11	Robert T. Garvin	Production de proteines actives contenant des residus de cystine
US5641663A (en)	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (fr)	1987-07-21	1992-02-11	Robert T. Garvin	Caracterisation et structure de genes pour protease a et protease b de streptomyces griseus
JPH0780930B2 (ja)	1985-12-26	1995-08-30	三井石油化学工業株式会社	α−オレフインの重合方法
JPH0645551B2 (ja)	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
ATE65403T1 (de)	1986-01-22	1991-08-15	Chugai Pharmaceutical Co Ltd	Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
CA1297005C (fr)	1986-01-22	1992-03-10	Masahiko Tamura	Agent pharmaceutique de traitement de la leucemie myeloide
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (fr) *	1986-02-21	1989-10-20	Genetica	Procede de preparation de la serum albumine humaine mature
EP0237019A3 (fr)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interféron conjugué et sa préparation à partir d'un gène recombinant
IT1203758B (it)	1986-03-27	1989-02-23	Univ Roma	Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DK179286D0 (da)	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
US4765980A (en) *	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (it) *	1986-06-20	1989-03-01	Sclavo Spa	Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (it)	1986-07-11	1988-11-16	Sclavo Spa	Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en)	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
AU624789B2 (en)	1987-02-19	1992-06-25	Amgen, Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
EP0286424B1 (fr) *	1987-04-09	1994-03-16	Delta Biotechnology Limited	Vecteur de levure
DE3855504T2 (de)	1987-04-22	1997-01-23	Chiron Corp	Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
FI107939B (fi)	1987-07-28	2001-10-31	Dsm Nv	Kluyveromyces isäntäkantana
JPH0622784Y2 (ja)	1987-08-04	1994-06-15	東洋シヤッター株式会社	オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja)	1987-08-19	1997-07-09	株式会社ビタミン研究所	遺伝子封入リポソームの製法
SE459586B (sv)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
PT88641B (pt)	1987-10-02	1993-04-30	Genentech Inc	Metodo para a preparacao de uma variante de adesao
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
JPH0811074B2 (ja)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (ja) *	1987-12-02	1998-08-27	株式会社ミドリ十字	異種蛋白質の製造方法、組換えｄｎａ、形質転換体
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
PT89484B (pt)	1988-01-22	1994-03-31	Gen Hospital Corp	Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
JPH01240191A (ja) *	1988-02-16	1989-09-25	Green Cross Corp:The	酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
DE58906966D1 (de)	1988-06-23	1994-03-24	Hoechst Ag	Mini-Proinsulin, seine Herstellung und Verwendung.
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
CN1033030C (zh)	1988-06-24	1996-10-16	唐化学原料公司	大环双官能螯合剂及其配合物和抗体共轭物的制备方法
JP2831073B2 (ja)	1988-06-24	1998-12-02	ザダウケミカルカンパニー	大環状二官能キレート剤、その錯体及びそれらの抗体接合体
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
AU633020B2 (en)	1988-07-23	1993-01-21	Novozymes Delta Limited	New secretory leader sequences
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2635115B1 (fr)	1988-08-05	1992-04-03	Rhone Poulenc Sante	Procede de preparation de la serum albumine humaine a partir d'une levure
WO1990001540A1 (fr)	1988-08-11	1990-02-22	California Biotechnology Inc.	Procede et vecteurs de stabilisation de l'expression de proteines heterologues
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0768377A1 (fr)	1988-09-02	1997-04-16	Protein Engineering Corporation	Production et sélection de protéines de liaison diversifiées de recombinaison
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (ja)	1988-10-06	1990-09-10	Tonen Corp	ヒト血清アルブミン断片
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (ja)	1988-10-26	1990-05-01	Tonen Corp	酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
EP0397834B1 (fr)	1988-10-28	2000-02-02	Genentech, Inc.	Procede d'identification de domaines actifs et de residus d'acides amines dans des polypeptides et des vaiantes d'hormones
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DK105489D0 (da) *	1989-03-03	1989-03-03	Novo Nordisk As	Polypeptid
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en)	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
ATE193541T1 (de)	1989-03-20	2000-06-15	Gen Hospital Corp	Insulinotropes hormon
EP0737750B1 (fr)	1989-03-21	2003-05-14	Vical, Inc.	Expression de séquences polynucléotidiques exogènes chez un vertébré
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0392300B1 (fr) *	1989-04-11	1992-08-26	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Utilisation d'au moins une cytokine pour l'obtention d'un médicament pour le traitement systémique des lésions prénéoplastiques
EP0395918A3 (fr)	1989-04-13	1991-10-23	Vascular Laboratory, Inc.	Complexe d'activateur de plasminogène de pro-urokinase pure liée de manière covalente par un pont disulfure à de la sérum albumine humaine
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (fr)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Polypeptides chimériques de CD4-immunoglobuline
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
DK0474727T3 (da)	1989-05-19	1998-01-12	Genentech Inc	HER2 ekstracellulært domæne
EP0399816B1 (fr)	1989-05-24	1995-12-20	Merck & Co. Inc.	Purification et caractérisation d'un facteur de croissance dérivé du rétinoblastane
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
ATE125869T1 (de) *	1989-06-09	1995-08-15	Gropep Pty Ltd	Wachstumshormonfusionsproteine.
JPH0327320A (ja)	1989-06-26	1991-02-05	Ajinomoto Co Inc	ヒトｂ細胞分化因子医薬組成物
EP0479909B1 (fr)	1989-06-29	1996-10-30	Medarex, Inc.	Reactifs bispecifiques pour le traitement du sida
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) *	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
CU22222A1 (es)	1989-08-03	1995-01-31	Cigb	Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
JP3115318B2 (ja)	1989-08-22	2000-12-04	イミュネックス・コーポレーション	Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (fr)	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Traitement de maladies et d'etats pathologiques
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (fr)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
ES2118066T3 (es)	1989-10-05	1998-09-16	Optein Inc	Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
FR2653020B1 (fr)	1989-10-17	1993-03-26	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
EP0452457B1 (fr)	1989-11-03	1997-08-20	Vanderbilt University	Procede d'administration in vivo de genes etrangers fonctionnels
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5116944A (en) *	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
JPH03201987A (ja)	1989-12-29	1991-09-03	Tonen Corp	ヒト血清アルブミン断片
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
EP0439442B1 (fr) *	1990-01-25	1996-03-06	Washington University	Protéine hybride, facteur X-LACI
JPH04211375A (ja)	1990-02-05	1992-08-03	Ajinomoto Co Inc	合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU7906691A (en)	1990-05-23	1991-12-10	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
DK0538300T3 (da)	1990-07-10	1994-10-10	Boehringer Ingelheim Int	O-Glycosyleret IFN-alfa
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (it)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JP3583420B2 (ja)	1990-10-05	2004-11-04	メダレツクス・インコーポレーテツド	二特異的試薬を用いた標的免疫化
JPH07108232B2 (ja)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja)	1990-10-26	1994-10-12	株式会社カンセイ	エアバック制御装置
AU8727291A (en)	1990-10-29	1992-06-11	Cetus Oncology Corporation	Bispecific antibodies, method of production, and uses thereof
FR2668368B1 (fr)	1990-10-30	1995-03-10	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
JPH0638771A (ja)	1990-10-31	1994-02-15	Tonen Corp	ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
WO1992009691A1 (fr)	1990-11-29	1992-06-11	Institut National De La Recherche Agronomique - I.N.R.A.	Nouveaux variants derives des interferons de type i, leur procede de production, et leurs applications
ES2113940T3 (es)	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
EP0503583A1 (fr)	1991-03-12	1992-09-16	Takeda Chemical Industries, Ltd.	Composition à libération prolongée à base d'erythropoiètine
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (fr)	1991-03-28	1999-06-23	Merck & Co. Inc.	Sous-unité C du facteur de croissance de cellules vasculaires endotheliales
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (fr)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Cassettes d'expression et vecteurs pour la secretion de serum albumine humaine dans des cellules pichia pastoris
IE921342A1 (en)	1991-04-26	1992-11-04	Surface Active Ltd	Novel antibodies, and methods for their use
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
FR2676070B1 (fr)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisation.
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1992022324A1 (fr)	1991-06-14	1992-12-23	Xoma Corporation	Fragments d'anticorps produits par des microbes et leurs conjugues
FR2677996B1 (fr)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
WO1993000109A1 (fr)	1991-06-28	1993-01-07	Genentech, Inc.	Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
US5223408A (en)	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (ja)	1991-07-29	1993-11-09	Tonen Corp	改良された酵母発現系
CA2114112A1 (fr)	1991-07-31	1993-02-18	David R. Hurwitz	Production de proteine transgenique
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
AU665599B2 (en) *	1991-11-08	1996-01-11	Hemosol Inc.	Hemoglobins as drug delivery agents
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
PT1696031E (pt)	1991-12-02	2010-06-25	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
JPH07506720A (ja)	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	アルツハイマー病のトランスジェニック動物モデル
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (fr)	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
WO1993016185A2 (fr)	1992-02-06	1993-08-19	Creative Biomolecules, Inc.	Proteine de liaison biosynthetique pour marqueur de cancer
WO1993017715A1 (fr)	1992-03-05	1993-09-16	Board Of Regents, The University Of Texas System	Agents diagnostiques et/ou therapeutiques cibles sur des cellules endotheliales neovasculaires
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
JPH06105020B2 (ja)	1992-06-09	1994-12-21	ホッペ・アーゲー	ラッチ及びロックアップシステム
SK155694A3 (en)	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	ヒト血清アルブミンの製造方法
FR2694294B1 (fr) *	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisateur.
MD1699F2 (ro)	1992-07-31	2001-07-31	Genentech, Inc.	Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (de)	1992-08-14	1998-12-03	Widmar Prof Dr Tanner	DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en) *	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) *	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (fr)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
NZ250844A (en)	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1994024160A2 (fr)	1993-04-21	1994-10-27	Brigham And Women's Hospital	Erythropoïetines-muteines a activite renforcee
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
AU703110B2 (en) *	1993-05-21	1999-03-18	Novo Nordisk A/S	Modified factor VII
ATE301201T1 (de)	1993-06-07	2005-08-15	Vical Inc	Für die gentherapie verwendbare plasmide
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (da) *	1993-07-08	1993-07-08	Novo Nordisk As	Peptid
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
EP0726772B1 (fr)	1993-08-09	2001-11-07	Edward Baral	Procede de sensibilisation de cellules cancereuses destinees a la lyse induite par cellules "tueuses"
IL192290A0 (en)	1993-08-17	2008-12-29	Kirin Amgen Inc	Erythropoietin analogs
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
AU7531094A (en)	1993-08-24	1995-03-21	Novo Nordisk A/S	Protracted glp-1
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
JPH09506262A (ja)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	特異的抗体の製造方法
CA2137206A1 (fr)	1993-12-09	1995-06-10	John A. Galloway	Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995016708A1 (fr)	1993-12-17	1995-06-22	Novo Nordisk A/S	Composes du type pro-insuline
DK144093D0 (fr)	1993-12-23	1993-12-23	Novo Nordisk As
PT744958E (pt)	1994-01-31	2003-11-28	Univ Boston	Bancos de anticorpos policlonais
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en) *	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en)	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
NZ290089A (en)	1994-07-27	1999-05-28	Queensland Inst Med Res	Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
JPH0853500A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	融合タンパク質および該タンパク質をコードする遺伝子
JPH0851982A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	ヒト血清アルブミンをコードする改変された遺伝子
JPH0859509A (ja)	1994-08-16	1996-03-05	Teijin Ltd	サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996014328A1 (fr)	1994-11-07	1996-05-17	Human Genome Sciences, Inc.	Polypeptide gamma appartenant a la famille des facteurs de necrose tumorale (fnt)
FR2726576B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
FR2726471B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AT403167B (de)	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
AU4415796A (en)	1994-12-07	1996-06-26	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
CA2206848A1 (fr)	1994-12-07	1996-06-13	Bionebraska, Inc.	Production de peptides au moyen de proteines de fusion de recombinaison
EP1621206A1 (fr) *	1994-12-12	2006-02-01	Beth Israel Deaconess Medical Center, Inc.	Cytokines chimeres et leur utilisation
WO1996020005A1 (fr)	1994-12-23	1996-07-04	Novo Nordisk A/S	Compositions a base de glp-1 et a action prolongee
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
JPH11507205A (ja)	1995-04-27	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	ヒト腫瘍壊死因子受容体
EP0822830B1 (fr)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Anticorps anti-IL-8 dérivés de xenosouris immunisées
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
AU5724996A (en)	1995-05-05	1996-11-21	Eli Lilly And Company	Single chain insulin with high bioactivity
JPH11505417A (ja)	1995-05-05	1999-05-21	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	ヒトケモカインベータ−８、ケモカインベータ−１、およびマクロファージ炎症性タンパク質−４
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5741815A (en)	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	腎機能改善剤
US5766620A (en)	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
ES2214551T3 (es)	1995-11-02	2004-09-16	Schering Corporation	Terapia de infusion continua de citocinas a baja dosis.
US6048964A (en)	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
CA2246431A1 (fr)	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Expression recombinee de proteines a partir de lignees cellulaires secretoires
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (de)	1996-02-28	1997-09-04	Bayer Ag	Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1975177T3 (da)	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
JP3794748B2 (ja) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	メタノール代謝系を有する微生物の培養法
WO1997033904A1 (fr)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Recepteurs contenant un domaine de mort cellulaire
WO1997033973A1 (fr)	1996-03-13	1997-09-18	Delta Biotechnology Limited	Regulation de la fermentation
CA2248538A1 (fr)	1996-03-14	1997-09-18	The Immune Response Corporation	Apport cible de genes codant l'interferon
WO1997033899A1 (fr)	1996-03-14	1997-09-18	Human Genome Sciences, Inc.	Molecule i induisant l'apoptose
CA2248136A1 (fr)	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Facteur i, ii et iii de liaison de steroides specifique a l'endometre humain
CA2248868A1 (fr)	1996-03-22	1997-09-25	Human Genome Sciences, Inc.	Molecule ii inductrice d'apoptose
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
WO1997039132A1 (fr)	1996-04-16	1997-10-23	University Of Miami	Preparations stabilisees de troponines humaines et modifications de ces troponines, procedes diagnostiques de dosage et trousses de dosage
US6497878B1 (en) *	1996-04-23	2002-12-24	Chugai Seiyaku Kabushiki Kaisha	Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
JP4172726B2 (ja) *	1996-05-22	2008-10-29	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
AU710069B2 (en) *	1996-06-11	1999-09-16	Roche Diagnostics Gmbh	Recombinant blood-coagulation proteases
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
AU733322B2 (en)	1996-07-15	2001-05-10	Chugai Seiyaku Kabushiki Kaisha	Novel VEGF-like factor
PE99498A1 (es)	1996-07-26	1999-01-21	Novartis Ag	Polipeptidos de fusion
US5959075A (en)	1996-08-02	1999-09-28	Zymogenetics, Inc.	Testis-specific insulin homolog polypeptides
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
CA2264200A1 (fr)	1996-08-16	1998-02-26	Human Genome Sciences, Inc.	Endokine alpha humaine
DE69738749D1 (de)	1996-08-16	2008-07-17	Schering Corp	Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
CA2263890C (fr)	1996-08-23	2013-05-14	Ludwig Institute For Cancer Research	Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
AU4199597A (en)	1996-09-09	1998-04-02	Novo Nordisk A/S	A cdna and peptide with relation to cancer and weight loss
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
AU7364696A (en) *	1996-09-18	1998-04-14	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
EP0931147A1 (fr)	1996-10-18	1999-07-28	Genentech, Inc.	ANTICORPS ANTI-ErbB2
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
DK0939804T4 (da)	1996-10-25	2011-07-18	Human Genome Sciences Inc	Neutrokin-alpha
JPH10134761A (ja)	1996-10-30	1998-05-22	Ebara Corp	イオン注入装置及びイオン注入方法
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
EP1306092A3 (fr)	1996-11-05	2003-05-07	Eli Lilly & Company	Utilisation d'analogues et de derivés de GLP-1 administrés de facon périphérique aux fins de la régulation de l'obésité
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
ES2237790T3 (es)	1996-11-12	2005-08-01	Novo Nordisk A/S	Uso de peptidos glp-1.
ATE549918T1 (de)	1996-12-03	2012-04-15	Amgen Fremont Inc	Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
WO1998030693A2 (fr)	1997-01-14	1998-07-16	Human Genome Sciences, Inc.	Recepteur 5 du facteur de necrose tumorale
JP2001527387A (ja) *	1997-01-24	2001-12-25	ノボノルディスクアクティーゼルスカブ	合成リーダーペプチド配列
EP1012274B2 (fr)	1997-01-28	2011-06-15	Human Genome Sciences, Inc.	Recepteur 4 (dr4:recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la trail ( apo-2l)
JP2001508783A (ja)	1997-01-29	2001-07-03	ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー	Ｐｅｇ化法
AU746826B2 (en)	1997-02-13	2002-05-02	Regents Of The University Of California, The	Production of mature proteins in plants
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) *	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
JP2002510193A (ja)	1997-03-31	2002-04-02	イーライ・リリー・アンド・カンパニー	グルカゴン様ペプチド−１類似体
TR199902553T2 (xx)	1997-04-14	2000-03-21	Micromet Gesellschaft F�R Biomedizinische Forschung Mbh	�nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
AR012448A1 (es) *	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU7705198A (en)	1997-05-30	1998-12-30	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU7830398A (en)	1997-06-11	1998-12-30	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr9
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
DE69726571T2 (de)	1997-09-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
ATE206618T1 (de)	1997-09-21	2001-10-15	Schering Corp	Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DK1017413T4 (da)	1997-09-23	2008-03-25	Rentschler Biotech Gmbh	Flydende formulering af interferon-beta
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2001519179A (ja) *	1997-10-09	2001-10-23	ヒューマンジノームサイエンシーズ，インコーポレイテッド	５３個のヒト分泌タンパク質
ES2303358T3 (es)	1997-11-03	2008-08-01	Human Genome Sciences, Inc.	Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
TR200001580T2 (tr)	1997-12-03	2000-12-21	Roche Diagnostics Gmbh	Spesifik etkinliği yüksek eritropoyetin
CA2312190A1 (fr)	1997-12-05	1999-06-17	Eli Lilly And Company	Formulations de glp-1
PT1037927E (pt)	1997-12-08	2004-10-29	Emd Lexigen Res Ct Corp	Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
ATE261935T1 (de) *	1997-12-08	2004-04-15	Bristol Myers Squibb Co	Neue metformin salze und verfahren
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (ko)	1997-12-29	2000-05-01	김충환	사람 인슐린 전구체의 제조방법
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
ATE366115T1 (de)	1998-02-13	2007-07-15	Amylin Pharmaceuticals Inc	Inotropische und diuretische effekte von exendin und glp-1
WO1999043706A1 (fr)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derives d'analogues de glp-1
EP1061947B1 (fr)	1998-03-13	2004-06-16	Novo Nordisk A/S	Solutions aqueuses stabilisees de glucagon comprenant des detergents
WO1999047161A1 (fr)	1998-03-19	1999-09-23	Bionebraska, Inc.	Regulation de l'appetit chez les humains par un compose se liant a un recepteur de peptide de type glucagon
DE19813802A1 (de)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (fr)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Nouvelle composition microsphere
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
CN1119352C (zh)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	人血清白蛋白在毕赤酵母中的表达与纯化
TWI277424B (en) *	1998-05-15	2007-04-01	Schering Corp	Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
NZ508823A (en)	1998-06-12	2003-10-31	Amylin Pharmaceuticals Inc	Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance or increased risk of a cardiovascular or cerebrovascular event
DE69933216T2 (de) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
CN1105727C (zh)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	重组人血清白蛋白的生产方法
BR9911457A (pt)	1998-06-24	2001-12-11	Univ Emory	Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
BR9911678A (pt)	1998-06-30	2001-03-20	Novo Nordisk As	Cristais de semeadura para a preparação de peptìdeos ou preteìnas.
WO2000004171A1 (fr)	1998-07-15	2000-01-27	Wisconsin Alumni Research Foundation	Traitement du diabete avec des cellules beta synthetiques
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
JP4624558B2 (ja)	1998-08-10	2011-02-02	ザガバメントオブザユナイテッドステイツオブアメリカ，アズレプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
HUP0103369A3 (en)	1998-08-28	2002-03-28	Lilly Co Eli	Use of insulinotropic peptides
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
NZ511488A (en)	1998-10-16	2003-10-31	Immunex Corp	Inhibitors of platelet activation and recruitment comprising an Ala residue and heterologous peptides capable of forming a stable secondary structure attached to a CD39 polypeptide
ATE355303T1 (de)	1998-10-23	2006-03-15	Amgen Inc	Methoden und zusammensetzungen zur prävention und behandlung der anämie
ATE365210T1 (de)	1998-10-30	2007-07-15	Novozymes As	Glykosylierte proteine mit reduzierter allergenität
CA2352538A1 (fr)	1998-11-30	2000-06-08	Eli Lilly And Company	Composes erythropoietiques
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
CA2358107C (fr)	1998-12-22	2011-08-23	Eli Lilly And Company	Formulation de longue conservation de peptide-1 de type glucagon
US20030190669A1 (en) *	1998-12-30	2003-10-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
CA2370189A1 (fr)	1999-04-09	2000-10-19	Craig A. Rosen	48 proteines secretees humaines
JP2002542183A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	成形可能な乾燥した医薬製剤
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE19921537A1 (de)	1999-05-11	2000-11-23	Dieter Hoersch	Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
SI1180121T1 (en)	1999-05-17	2004-04-30	Conjuchem, Inc.	Long lasting insulinotropic peptides
KR20020018197A (ko)	1999-05-19	2002-03-07	추후보정	Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6660716B1 (en)	1999-06-21	2003-12-09	Eli Lilly And Company	Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
US20020048571A1 (en)	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
JP2003505043A (ja)	1999-07-19	2003-02-12	ジーピーシーバイオテックインコーポレイテッド	血清アルブミンのキメラポリペプチド及びそれらに関する利用
JP2003510028A (ja)	1999-08-17	2003-03-18	ヒューマンジノームサイエンシーズ，インコーポレイテッド	２５個のヒト分泌タンパク質
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TW200528436A (en)	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
CA2388432A1 (fr)	1999-10-21	2001-04-26	Monsanto Company	Modification post-traductionnelle de proteines de recombinaison produites dans les plantes
WO2001030320A1 (fr)	1999-10-22	2001-05-03	Amgen Inc.	Microparticules biodegradables contenant une nouvelle proteine stimulant l'erythropoietine
DE60037535D1 (de)	1999-11-03	2008-01-31	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2324801A1 (fr)	1999-11-10	2001-05-10	Andrew Gordon Swick	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
EP1228214A2 (fr)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Formes d'erythropoietine dotees de proprietes ameliorees
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
JP2003523323A (ja)	1999-12-06	2003-08-05	ザジェネラルホスピタルコーポレーション	膵臓幹細胞および移植におけるその使用
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (fr)	2000-01-18	2003-01-02	Pfizer Products Inc.	Utilisations de composés modulant la liaison entre l'AGRP et les récepteurs à la mélanocortine
HUP0204281A3 (en)	2000-01-27	2007-03-28	Lilly Co Eli	Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
AU2001228327A1 (en)	2000-01-31	2001-08-14	Novo-Nordisk A/S	Crystallisation of a glp-1 analogue
JP2003526671A (ja)	2000-03-14	2003-09-09	レストラゲン，インコーポレイテッド	幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1274720A4 (fr)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Proteines fusionnees a l'albumine
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2001081405A2 (fr)	2000-04-21	2001-11-01	Amgen Inc.	Methodes et compositions destinees a la prevention et au traitement de l'anemie
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
JP3967594B2 (ja) *	2000-05-15	2007-08-29	エフ．ホフマン−ラロシュアーゲー	新しい薬剤組成物
US20020061838A1 (en)	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
PT1695983E (pt)	2000-06-16	2009-05-05	Lilly Co Eli	Análogos do peptídeo-1 do tipo glucagon
WO2002022151A2 (fr)	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Utilisation de peptides glp-1 et glp-2
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en)	2000-12-04	2002-06-18	Biovitrum Ab	Novel method and use
ES2311560T3 (es)	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
EP2186824A3 (fr)	2000-12-13	2010-09-22	Eli Lilly & Company	Posologie de traitement chronique à l'aide de peptides insulinotropiques de type glucagon
US7199217B2 (en)	2000-12-13	2007-04-03	Eli Lilly And Company	Amidated glucagon-like peptide-1
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (fr)	2001-02-01	2002-08-29	Drucker Daniel J	Renforcement de l'activite de glp-2
KR100399337B1 (ko)	2001-02-07	2003-09-26	드림바이오젠 주식회사	단백질의 무세포 번역후수식법
WO2002069994A2 (fr)	2001-03-07	2002-09-12	Novo Nordisk A/S	Utilisation combinee de derives d'analogues glp-1 et de ligands ppar
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (fr)	2001-04-24	2002-10-31	Restoragen, Inc.	Procedes et compositions pour le traitement d'etats lies a la resistance a l'insuline
WO2002097038A2 (fr)	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Proteines hybrides beta-1 de chimiokine
JP2005506956A (ja)	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
EP1397124B1 (fr)	2001-06-20	2006-11-29	Merck Sante	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US20030119734A1 (en)	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
JP2005501058A (ja)	2001-07-31	2005-01-13	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンテッドバイザセクレタリーデパートメントオブヘルスアンドヒューマンサービシーズザナショナルインステ	Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
AU2002327430A1 (en)	2001-08-08	2003-02-24	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
EP1423136A4 (fr)	2001-08-10	2007-07-25	Epix Pharm Inc	Conjugues de polypeptides ayant des demi-vies de circulation accrues
CA2458371A1 (fr)	2001-08-23	2003-03-06	Eli Lilly And Company	Analogues de glp-1 (glucagon-like peptide 1)
WO2003030821A2 (fr)	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
EP2042196B1 (fr)	2001-10-10	2016-07-13	ratiopharm GmbH	Remodelage et glycoconjugation de facteur stimulant les colonies de granulocytes (G-CSF)
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
EP1463752A4 (fr)	2001-12-21	2005-07-13	Human Genome Sciences Inc	Proteines de fusion d'albumine
WO2003054182A2 (fr)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production de butyrylcholinesterases par des mammiferes transgeniques
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
WO2003076567A2 (fr)	2002-03-05	2003-09-18	Eli Lilly And Company	Proteines hybrides g-csf heterologues
MXPA04012496A (es) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
CA2513213C (fr) *	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
US8986607B2 (en) *	2003-02-27	2015-03-24	Baxter International Inc.	Method for the validatable inactivation of pathogens in a biological fluid by irradiation
JP4629047B2 (ja)	2003-06-12	2011-02-09	イーライリリーアンドカンパニー	Ｇｌｐ−１アナログ複合タンパク質
JP5010923B2 (ja) *	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
JP2009504157A (ja)	2005-08-12	2009-02-05	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合タンパク質
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (fr) *	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
AU2007258609B2 (en)	2006-06-07	2013-01-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2838833A1 (fr) *	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Composes pro-coagulants et leurs procedes d'utilisation

2001
- 2001-04-12 EP EP01932549A patent/EP1274720A4/fr not_active Ceased
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP10075064A patent/EP2206720A1/fr not_active Withdrawn
- 2001-04-12 EP EP06015131A patent/EP1803730A1/fr not_active Withdrawn
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 EP EP01937179A patent/EP1276856A4/fr not_active Withdrawn
- 2001-04-12 EP EP01944114A patent/EP1276756A4/fr not_active Withdrawn
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 EP EP01932546A patent/EP1274719A4/fr not_active Ceased
- 2001-04-12 CA CA002405563A patent/CA2405563A1/fr not_active Abandoned
- 2001-04-12 EP EP06076852A patent/EP1832599A3/fr not_active Ceased
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 EP EP10075375A patent/EP2298355A3/fr not_active Withdrawn
- 2001-04-12 EP EP01941457A patent/EP1278544A4/fr not_active Ceased
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/fr not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/fr not_active Ceased
- 2001-04-12 EP EP10075499A patent/EP2357008A1/fr not_active Withdrawn
- 2001-04-12 EP EP10075388A patent/EP2311872A1/fr not_active Withdrawn
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/fr not_active Ceased
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 CA CA002405525A patent/CA2405525A1/fr not_active Abandoned
- 2001-04-12 EP EP08075909A patent/EP2067488A1/fr not_active Withdrawn
- 2001-04-12 CA CA002405550A patent/CA2405550A1/fr not_active Abandoned
- 2001-04-12 EP EP10075164A patent/EP2213743A1/fr not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 CA CA002405709A patent/CA2405709A1/fr not_active Abandoned
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP10075391A patent/EP2295456A1/fr not_active Ceased
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/fr not_active Ceased
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/fr not_active Ceased
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA002405912A patent/CA2405912A1/fr not_active Abandoned
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/fr not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/fr not_active Ceased
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 EP EP08075327A patent/EP1983055A1/fr not_active Withdrawn
- 2001-04-12 EP EP01934875A patent/EP1278767A4/fr not_active Withdrawn
- 2001-04-12 CA CA2747325A patent/CA2747325A1/fr not_active Abandoned
- 2001-04-12 EP EP10075316A patent/EP2275557A1/fr not_active Withdrawn
- 2001-04-12 EP EP01938994A patent/EP1276849A4/fr not_active Withdrawn
- 2001-04-12 EP EP10075387A patent/EP2267026A1/fr not_active Withdrawn
- 2001-04-12 CA CA2405557A patent/CA2405557C/fr not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/fr not_active Ceased
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA002405701A patent/CA2405701A1/fr not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/fr not_active Ceased
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
2016
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2003530839A (ja)	2003-10-21
US7785599B2 (en)	2010-08-31
AU2001259063A1 (en)	2001-10-30
US20120141449A1 (en)	2012-06-07
EP1278544A2 (fr)	2003-01-29
WO2001077137A9 (fr)	2002-05-02
EP1983055A1 (fr)	2008-10-22
EP1803730A1 (fr)	2007-07-04
FR16C0043I2 (fr)	2020-04-10
EP1278767A4 (fr)	2003-11-12
US20030171267A1 (en)	2003-09-11
US20140010798A1 (en)	2014-01-09
WO2001079258A1 (fr)	2001-10-25
EP1276856A4 (fr)	2004-06-09
CA2405557C (fr)	2013-09-24
EP2216409A1 (fr)	2010-08-11
EP1274720A1 (fr)	2003-01-15
JP2004506407A (ja)	2004-03-04
WO2001079480A1 (fr)	2001-10-25
EP1276849A4 (fr)	2004-06-09
CA2405550A1 (fr)	2001-10-25
EP2357008A1 (fr)	2011-08-17
EP1276756A4 (fr)	2004-06-09
JP2003530838A (ja)	2003-10-21
US20180200346A1 (en)	2018-07-19
US20030125247A1 (en)	2003-07-03
JP2011217750A (ja)	2011-11-04
WO2001079271A9 (fr)	2002-02-28
US20140004095A1 (en)	2014-01-02
US6905688B2 (en)	2005-06-14
WO2001079444A3 (fr)	2002-05-23
US20030199043A1 (en)	2003-10-23
US20040171123A1 (en)	2004-09-02
WO2001079442A2 (fr)	2001-10-25
AU2001264563A1 (en)	2001-10-30
EP2275557A1 (fr)	2011-01-19
CA2405912A1 (fr)	2001-10-18
DK2236152T3 (da)	2014-07-07
EP1274720A4 (fr)	2004-08-18
JP2014057589A (ja)	2014-04-03
AU2001261024A1 (en)	2001-10-30
ES2484966T3 (es)	2014-08-12
US20080131399A1 (en)	2008-06-05
EP2236152A1 (fr)	2010-10-06
WO2001079443A3 (fr)	2002-02-21
EP1278767A1 (fr)	2003-01-29
US10080785B2 (en)	2018-09-25
WO2001079442A3 (fr)	2002-06-06
US20080261877A1 (en)	2008-10-23
US20070287173A9 (en)	2007-12-13
US20100189686A1 (en)	2010-07-29
AU2001274809A1 (en)	2001-10-30
US8946156B2 (en)	2015-02-03
AU2001266557A1 (en)	2001-10-23
US20080269125A1 (en)	2008-10-30
WO2001079271A1 (fr)	2001-10-25
US6994857B2 (en)	2006-02-07
US20050266533A1 (en)	2005-12-01
AU2001259066A1 (en)	2001-10-30
JP2003531590A (ja)	2003-10-28
EP1276856A1 (fr)	2003-01-22
EP2236152B1 (fr)	2014-06-04
DK2216409T3 (en)	2015-01-05
EP2298355A2 (fr)	2011-03-23
US20050266532A1 (en)	2005-12-01
US20130266553A1 (en)	2013-10-10
US20120252732A1 (en)	2012-10-04
CA2405525A1 (fr)	2001-10-25
EP2213743A1 (fr)	2010-08-04
CA2405709A1 (fr)	2001-10-25
US7507414B2 (en)	2009-03-24
ES2529300T3 (es)	2015-02-18
US20120141415A1 (en)	2012-06-07
JP2003530852A (ja)	2003-10-21
US20080267962A1 (en)	2008-10-30
EP2206720A1 (fr)	2010-07-14
AU2001262942A1 (en)	2001-10-30
EP2267026A1 (fr)	2010-12-29
US20080269127A1 (en)	2008-10-30
US20030219875A1 (en)	2003-11-27
WO2001077137A1 (fr)	2001-10-18
EP2295456A1 (fr)	2011-03-16
US20080269128A1 (en)	2008-10-30
EP1276756A1 (fr)	2003-01-22
EP1832599A3 (fr)	2007-11-21
WO2001079443A2 (fr)	2001-10-25
CA2405563A1 (fr)	2001-10-25
CA2405701A1 (fr)	2001-10-25
CA2747325A1 (fr)	2001-10-25
US20090285816A9 (en)	2009-11-19
US6926898B2 (en)	2005-08-09
WO2001079258A9 (fr)	2002-02-28
US7482013B2 (en)	2009-01-27
CA2405557A1 (fr)	2001-10-25
EP2311872A1 (fr)	2011-04-20
EP1274719A2 (fr)	2003-01-15
EP1278544A4 (fr)	2004-08-18
EP1832599A2 (fr)	2007-09-12
US9775888B2 (en)	2017-10-03
US9821039B2 (en)	2017-11-21
WO2001079444A2 (fr)	2001-10-25
FR16C0043I1 (fr)	2016-12-09
WO2001079480A9 (fr)	2003-09-18
JP2003530846A (ja)	2003-10-21
EP1274719A4 (fr)	2004-05-19
US9849162B2 (en)	2017-12-26
EP2067488A1 (fr)	2009-06-10
EP1276849A2 (fr)	2003-01-22
EP2216409B1 (fr)	2014-12-03
US20040010134A1 (en)	2004-01-15
EP2298355A3 (fr)	2011-06-29
JP2003530847A (ja)	2003-10-21
US20110280830A9 (en)	2011-11-17
US20080269126A1 (en)	2008-10-30

Publication	Publication Date	Title
FR16C0043I1 (fr)	2016-12-09
BE2015C062I2 (fr)	2021-01-28
BE2013C060I2 (fr)	2020-12-15
JP2002543498A5 (fr)	2007-07-12
BE2011C041I2 (fr)	2020-08-20
JP2003526978A5 (fr)	2008-02-28
BRPI0110940B8 (fr)	2021-05-25
JP2003510788A5 (fr)	2007-11-08
JP2003514716A5 (fr)	2007-12-27
JP2003527891A5 (fr)	2008-01-24
JP2001339853A5 (fr)	2006-12-07
JP2001305432A5 (fr)	2007-06-14
JP2003505773A5 (fr)	2010-07-01
JP2002199236A5 (fr)	2008-01-10
JP2003516873A5 (fr)	2007-12-27
JP2002048400A5 (fr)	2007-08-23
IN191958B (fr)	2004-01-24
AU2002213435A8 (fr)	2005-10-13
CN3141406S (fr)	2000-03-08
CN3143089S (fr)	2000-03-22
CN3144927S (fr)	2000-04-05
CN3144584S (fr)	2000-04-05
CN3137256S (fr)	2000-02-02
CN3135640S (fr)	2000-01-19
CN3139603S (fr)	2000-02-23